Caris Life Sciences Inc., of Irving, Texas, was granted a patent in the People’s Republic of China covering Caris Molecular Intelligence, the company’s molecular profiling service. In China, about 3.5 million people are diagnosed with cancer each year. Caris also has been granted patents previously in Singapore and South Africa.
HONG KONG – In order to keep up with the biopharmaceutical industry’s rapid growth, South Korea is stepping up efforts to attract and nurture more research and development talent.
SHANGHAI – China has issued two legal announcements in its bid to root out corruption in the pharmaceutical industry. They focus on both the demand and supply side of corruption in China, targeting pharma companies that pay bribes and the doctors who accept them.
HONG KONG – Swiss biopharmaceutical Actelion Ltd. is seeking regulatory approval in China for its Zavesca (miglustat) to treat Niemann-Pick Type C (NPC), a rare disease for which there is little information and no treatment available in the country.
SHANGHAI – Shenzhen Hepalink Pharmaceutical Co. Ltd. announced a stock purchase agreement to fully acquire Scientific Protein Laboratories LLC (SPL), of Waunakee, Wis.
Mylan Inc., of Pittsburgh, appointed Rakesh Bamzai president, India commercial and emerging markets. Previously, Bamzai was president of marketing at Biocon Ltd., of Bangalore, India.
HONG KONG – After a lost 2013, companies in China are expected to start issuing shares again this year and this could prove a boon to biopharmaceutical companies that are generally underrepresented in the markets in Shanghai and Shenzhen.
HONG KONG – In one of the first issues since Mainland China regulator lifted a ban on initial public offerings (IPOs), Zhejiang Wolwo Bio-Pharmaceutical Co. (SZ: 300357) plans to offer as many as 30 million shares for as much as ¥20.05 (US$3.30) per share.
Tauriga Sciences Inc., of New York, said it received a comprehensive update from Immunovative Therapies Ltd. (ITL), of Shoham, Israel, including news that ITL plans to relaunch clinical trials in Thailand in metastatic cancer and in Israel in liver cancer later this month.
Multinational biopharmaceutical companies will see the door to China swing open wider this year if the country’s new leadership delivers on promises made in November to let market forces dominate.
RSS